Janssen Search
Search results
Outpacing AMR Infections Through Innovations
Outpacing AMR Infections Through Innovations As scientists in the field of infectious diseases, it is our life’s work to research and develop solutions to some of the world’s most challenging and dangerous health concerns. While we have made tremendous ...
Johnson & Johnson’s nipocalimab granted U.S. FDA Fast Track designation to reduce the risk of fetal neonatal alloimmune thrombocytopenia (FNAIT) in alloimmunized pregnant adults
Mar 26, 2024 United States FNAIT is a rare disease that occurs when a pregnant person’s immune system attacks fetal platelets, resulting in the risk of internal bleeding, which can be life threatening to the fetus or newborn The Phase 3 FREESIA program is ...
Janssen Postdoctoral Program
Article Type: Other The Janssen Postdoctoral (Post-Doc) Program, available in the United States and Europe, offers scientists just starting out in their careers the opportunity to gain experience in an industry setting while gaining the skills necessary ...
Remo Colarusso
Remo Colarusso Vice President Janssen Supply Chain Remo Colarusso is Vice President, Janssen Supply Chain (JSC) at Johnson & Johnson. In this capacity, Remo is responsible for the global manufacturing and supply management of all J&J ...
Zili Li, M.D., M.P.H.
ZILI LI, M.D., M.P.H. HEAD OF ASIA PACIFIC R&D JANSSEN RESEARCH & DEVELOPMENT As Head of Asia Pacific R&D, Zili oversees all R&D activities within Asia Pacific, leading over 1,400 science professionals dedicated to delivering ...
Real World Data Clinical Design Operations
Our goal is to unleash the value of real-world data (RWD) in the era of artificial intelligence (AI) through rigorous analysis and strategic collaborations. Real-World Data in Clinical Design and Operations At Janssen R&D, we’re harnessing the power ...
Technology-Enabled Genomics
The rapid evolution of high-throughput sequencing technologies empowers us to collect high dimensional genomics data on huge numbers of patients, enabling the discovery of novel biomarkers, mechanisms of action and drug targets. Technology-Enabled ...
ASCO GU 2022
Leadership Perspectives Welcome to the Janssen Oncology ASCO GU Virtual Newsroom At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are driven by our vision to eliminate cancer. As we pursue this ambitious goal, we are pleased to share ...
New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year
Mar 09, 2024 United States JNJ-2113 long-term extension FRONTIER 2 study demonstrated sustained efficacy from Week 16 to Week 52 and safety results consistent with previously reported data (FRONTIER 1 Study) in a late-breaking oral presentation at the ...
Opening Vaccines Launch Facility speakers
Oct 24, 2018 Speakers Inspiring and engaging presentations and panal discussions will hightlight why it is important to "invest locally, to protect globally". View the complete program of the symposium. Moderator Guest speakers/panelists ...